Gecacitinib

PreclinicalSmall molecule

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Gecacitinib is one of 150 small molecule programs targeting Lymphoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

149

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

MyelofibrosisActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Cervical CancerActive, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

MyelofibrosisPreclinical

Active, not recruiting

Non-Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Cervical CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Velban

EEastern Cooperative Oncology Group

Preclinical

15 2

Zofran

Novartis

Preclinical

2 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 4

Tafasitamab

Incyte

Preclinical

7 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Decadron

QQuince Therapeutics S.p.A.

Systemic Therapy

1 10

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Non-Small Cell Lung Cancer

NCT06903377

Phase 1/2Recruiting

Lymphoma

NCT06883526

Q4 2027

Phase 1/2Recruiting

Cervical Cancer

NCT07080216

Phase 1/2Not yet recruiting

Advanced Solid Tumors

NCT07142837

Phase 2Not yet recruiting

Acute Graft Versus Host Disease

NCT07197112

Q4 2028

Phase 1/2Not yet recruiting

Refractory

NCT07476872

Clinical

Trials by Indication[1]

Myelofibrosis2 trials

Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis

Not yet recruiting·NNanfang Hospital, Southern Medical University·N/A·NCT07440654·40 enrolled

Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07471503·39 enrolled

Cervical Cancer1 trial

Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT07080216·120 enrolled

Non-Small Cell Lung Cancer1 trial

Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT06903377·50 enrolled

Lymphoma1 trial

Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT06883526·60 enrolled

Safety and Efficacy1 trial

Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy

Recruiting·YYujun DONG·Phase 1/2·NCT07012304·24 enrolled

3 more indications

Advanced Solid Tumors1 trial

Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors

Not yet recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT07142837·153 enrolled

Refractory1 trial

Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT07476872·33 enrolled

Acute Graft Versus Host Disease1 trial

Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy

Not yet recruiting·RRuijin Hospital·Phase 2·NCT07197112·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Gecacitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gecacitinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gecacitinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou Zelgen Biopharmaceuticals Co.,Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Gecacitinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Myelofibrosis2 trials

Cervical Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Lymphoma1 trial

Safety and Efficacy1 trial

Advanced Solid Tumors1 trial

Refractory1 trial

Acute Graft Versus Host Disease1 trial

References

Drug Info

Quick Facts

Related News